Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties.

Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA.

Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration. Protein binding: 70%. Metabolism: Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound. Route of elimination: Urine (69%), as metabolites. Half life: 10-20 hours.

Hypersensitivity, myasthenia gravis, narrow-angle glaucoma

This medication should not be used during pregnancy unless the benefits outweigh the risks.

This medication may pass into breast milk. If you are a breast-feeding mother and are taking bromazepam, it may affect your baby.

Adverse effects are sedation, drowsiness, hypotension, nausea and vomiting.

1.5-3 mg TID for outpatient therapy; 6-12 mg BID to TID for severe cases.